Aurobindo gets USFDA approval for anti-hypertensive tablets

New Delhi, June 26 (UNI) Aurobindo Pharma Ltd (APL) has received tentative approval from the USFDA for its anti-hypertensive tablets Quinapril Hydrochloride and Hydrochlorothiazide.

Both the tablets in the strengths of 10mg, 12.5mg, 20mg, 12.5mg and 20mg, 25mg are the generic equivalent of Pfizer Pharmaceuticals's Accuretic Tablets.

This is the fifth anti-hypertensive tablet of the company bagging USFDA's nod. With this, the company's product basket for the US market has gone up to 45, a statement said today.

Meanwhile, the company in a separate note to the BSE said the Andhra Pradesh High Court has approved the merger of APL Life Sciences Ltd and Senor Organics Pvt Ltd into the company and the utilisation of share premium account of the company.

Further, no shares would be issued by the company in consideration for the merger as both APL Life and Senor are wholly-owned subsidiary Companies.

KPMG India Pvt Ltd has assisted in the process of merger, it added.

UNI